
    
      Patients with AGC who achieved objective response or stable disease after 2-6 months of
      first-line chemotherapy were randomly assigned to one of two groups, to receive either S-1
      (40 mg for BSA<1.25 m2, 50 mg for 1.25≤BSA<1.50 m2 and 60 mg for BSA≥1.50 m2 b.i.d. on days
      1-14, q3w) as maintenance therapy or observation. The treatment will continue until disease
      progression or unacceptable toxicity.
    
  